The neural and neuroimmune mechanisms behind myocardial infarction-triggered cardiac events, immune responses and activation of the nervous system remain largely unexplored. The heart and the brain talk to each other in what is known as cardioception. This communication between the two organs is orchestrated through neurons of the vagus nerve or the dorsal root ganglia, among others. Researchers from the University of California, San Diego have now shown that the dynamics of these interactions may play a crucial role in modulating inflammation, repair and cardiac functioning.
Acute inflammation is a physiological and host defense response to cardiac injury after suffering myocardial infarction (MI), which programmes cardiac repair and wound healing. Leukocyte-mediated innate inflammatory response is crucial to clear ischemic injury during MI; whilst macrophages produce specialized pro-resolving mediators such as maresin 1, the therapeutic potential of exogenous maresin 1 in cardiac repair is not clear.
Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram software for the assessment of arrhythmias. In November, the Santa Clara, Calif.-based company received a Not Substantially Equivalent determination from the agency on its 510(k) application, which could have substantially delayed commercialization. Following a plan disclosed Nov. 28, the company resolved the agency's issues through an appeal process and active engagement and obtained clearance much more quickly than expected.
The FDA has cleared AD-NP1, a drug developed by University of California, Los Angeles (UCLA) for heart tissue regeneration, to enter clinical trials. The monoclonal antibody blocks the production of ENPP1 protein, which was found to interfere with healing after a heart attack.
Many patients who survive myocardial infarction go on to experience heart failure. Researchers at Qilu Hospital of Shandong University found that bone morphogenetic protein 1 (BMP1) was upregulated in patients after myocardial infarction, as well as in a mouse model of the same condition.
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYH-2046 for heart failure after acute myocardial infarction.
When every minute matters, quickly determining which patients in the emergency department need urgent care for myocardial infarction can save lives. Researchers at the University Hospital Münster in Münster, Germany, developed a deep learning model that can detect features on electrocardiograms that more accurately identifies which patients require urgent revascularization than clinicians and provides results faster than high-sensitivity troponin lab tests.
With rates of preeclampsia skyrocketing, the U.S. FDA’s510(k) clearance of Roche Holding AG’s Elecsys test for preeclampsia offers some hope of reducing the number of women and infants who die or experience life-long consequences from the development of dangerously high blood pressure during late pregnancy and in the days immediately following delivery.
Heart disease remains the leading cause of death worldwide, and developing new therapeutic approaches constitutes an urgent healthcare priority. Almost one-third of patients surviving myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria.
GE Healthcare Technologies Inc. received U.S. FDA approval for its novel radiotracer, Flyrcado (flurpiridaz F-18), for use in the diagnosis of myocardial ischemia or infarction in patients with known or suspected coronary artery disease.
